Klinikum Oldenburg

A cardiovascular-motor axis framework for perfusion-mediated motor impairment

Cardiovascular disease is the leading cause of death worldwide, and among survivors of heart failure, peripheral arterial disease, valvular disease, and atrial fibrillation many develop motor impairment: weakness, slow gait, sarcopenia, frailty. These deficits are usually attribu...

Agranulocytosis associated with metamizole among EudraVigilance reports involving methotrexate for rheumatoid arthritis

Methotrexate (MTX) can induce adverse drug reactions (ADRs) including severe haematotoxic events. This study analyses whether agranulocytosis is disproportionately reported in spontaneous reports involving MTX for rheumatoid arthritis (RA) when use of metamizole, a non-opioid ana...

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

Abstract Background Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of the combination of venetoclax (VEN) with azacitidine (AZA) or decitabine (DAC) in the European Union in 2021 for the treatment of patients wit...

Mapping pediatric cardiac troponin testing worldwide: results from the IFCC survey on emerging applications, standardization needs and access

OBJECTIVES: Limited guidance on the use and interpretation of cardiac troponin (cTn) testing in pediatric populations has restricted its broader adoption, despite the significant burden of congenital and acquired cardiac conditions in children. This survey aimed to evaluate globa...